Log In
Print this Print this

CD133+ bone marrow stem cells

  Manage Alerts
Collapse Summary General Information
Company Miltenyi Biotec GmbH
DescriptionAutologous prominin 1 (PROM1; CD133) bone marrow-derived stem cells
Molecular Target
Mechanism of Action 
Therapeutic ModalityCell therapy: Stem cell
Latest Stage of DevelopmentPhase III
Standard IndicationIschemia / reperfusion injury
Indication DetailsTreat ischemic heart disease
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today